BioPharma Dive March 25, 2025
The startup claims one of its experimental medicines could be more effective than the geographic atrophy drugs Syfovre and Izervay.
Character Biosciences, a biotechnology startup developing treatments for vision loss, said Tuesday it raised $93 million in a Series B round.
The financing will help Character bring its two most advanced programs into clinical testing. One, dubbed CTX114, is being tested in geographic atrophy, a common eye condition and an advanced stage of age-related macular degeneration, or AMD. The other, CTX203, is designed to halt progression in people with “intermediate” AMD, so they don’t develop geographic atrophy or other forms of advanced disease. Both drug prospects should begin Phase 1 trials this year.
In geographic atrophy, Character aims to challenge...
Today's Sponsors
Today's Sponsor